Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zavyalova, Elena ^a,b   Samoylenkova, Nadezhda ^b,c   Revishchin, Alexander ^c   Golovin, Andrey ^a,b   Pavlova, Galina ^b,c   Kopylov, Alexey ^a,b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b 'APTO PHARM' LTD   (Russian Federation)

^c INSTITUTE OF GENE BIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; HIRULOG; RA 36 APTAMER; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; ANTITHROMBIN; FIBRINOGEN; FIBRINOLYTIC AGENT; GUANINE QUADRUPLEX; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; ENZYME ASSAY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MURINAE; NONHUMAN; PROTHROMBIN TIME; SINGLE DRUG DOSE; THROMBOSIS; TURBIDIMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; MALE; METABOLISM; MOUSE; PATHOLOGY;

MURINAE;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; APTAMERS, NUCLEOTIDE; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBRINOGEN; FIBRINOLYTIC AGENTS; G-QUADRUPLEXES; HIRUDINS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBIN; THROMBOSIS;

EID: 84906996224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107113     Document Type: Article

References (59)

1. Monroe DM, Hoffman M (2006) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26: 41-48.
2. Davie EW, Fujikawa K, Kisiel W (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
3. Pudusseri A, Shameem R, Spyropoulos AC (2013) A new paradigm shift in antithrombotic therapy. Front Pharmacol 4: 1-7.
4. Nutescu EA, Shapiro NL, Chevalier A, Amin AN (2005) A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 72: S2-S6.
5. De Cristofaro R, De Candia E (2003) Thrombin domains: structure, function and interaction with platelet receptors. J Thromb Thrombolysis 15: 151-163.
6. Nutescu EA, Wittkowsky AK (2004) Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 38: 99-109.
7. Corral-Rodriguez MA, Macedo-Ribeiro S, Pereira PJB, Fuentes-Prior P (2010) Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications. J Med Chem 53: 3847-3861.
8. Lancellotti S, De Cristofaro R (2009) Nucleotide-derived thrombin inhibitors: a new tool for an old issue. Cardiovasc Hematol Agents Med Chem 7: 19-28.
9. Bouchard PR, Hutabarat RM, Thompson KM (2010) Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50: 237-257.
10. Keefe AD, Schaub RG (2008) Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol 8: 147-152.
11. Bock LC, Griffin LC, Latheam JA, Vermass EH, Toole JJ (1992) Selection of single stranded DNA molecules that bind and inhibit human thrombin. Nature 355: 564-566.
12. Macaya RF, Schultze P, Smith FW, Roet JA, Feigon J (1993) Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA 90: 3745-3749.
13. Ponikova S, Tluckova K, Antalik M, Viglasky V, Hianik T (2011) The circular dichroism and differential scanning calorimetry study of the properties of DNA aptamer dimers. Biophys Chem 155: 29-35.
14. White R, Rusconi C, Scardino E, Wolberg A, Lawson J, et al. (2001) Generation of species cross-reactive aptamers using 'Toggle' SELEX. Mol Ther 4: 567-573.
15. Rusconi CP, Yeh A, Lyerly H, Jeffrey K, Lawson H, et al. (2000) Blocking the initiation of coagulation by RNA aptamers to factor VIIa. J Thromb Haemost 84: 841-848.
16. Vavalle JP, Cohen MG (2012) The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol 8: 371-382.
17. Krishnan A, Vogler EA, Sullenger BA, Becker RC (2013) The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. J Thromb Thrombolysis 35: 48-56.
18. Gopinath SCB, Shikamoto Y, Mizuno H, Kumar PKR (2006) A potent anticoagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway. J Thromb Haemost 95: 767-771.
19. Buddai SK, Layzer JM, Lu G, Rusconi CP, Sullenger BA, et al. (2010) An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J Biol Chem 285: 5212-5223.
20. Woodruff RS, Xu Y, Layzer J, Wu W, Ogletreee ML, et al. (2013) Inhibiting the intrinsic pathway of coagulation with a FXII-targeting RNA aptamer. J Thromb Haemost 11: 1364-1373.
21. Parunov LA, Soshitova NP, Fadeeva OA, Balandina AN, Kopylov KG, et al. (2014) Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: Studies of spatial dynamics of fibrin clot formation in hemophilia A. Thromb Res 133: 112-119.
22. Gal SW, Amontov S, Urvil PT, Vishnuvardhan D, Nishikawa F, et al. (1998) Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function. Eur J Biochem 252: 532-562.
23. Bae O-N (2012) Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 35: 1693-1699.
24. Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, et al. (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22: 1423-1428.
25. Nimjee SM, Lohrmann JD, Wang H, Snyder DJ, Cummings TJ, et al. (2012) Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Mol Ther 20: 391-397.
26. Diener JL, Lagasse HAD, Duerschmied D, Merhi J, Tanguay J-F, et al. (2009) Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 7: 1155-1162.
27. Golovin AV, Kopylov AM, Reshetnikov RV, Zavyalova EG, Pavlova GV, et al. (2011) Anti-thrombosis aptamers and method for stabilizing the structure thereof. PCT Patent 2011/075004, June 23, 2011.
28. Zavyalova E, Golovin A, Reshetnikov R, Mudrik N, Panteleyev D, et al. (2011) Novel modular DNA aptamer for human thrombin with high anticoagulant activity. Curr Med Chem 18: 3343-3350.
29. Zavyalova E, Golovin A, Timoshenko T, Babiy A, Pavlova G, et al. (2012) DNA aptamers for human thrombin with high anticoagulant activity demonstrate target- and species-specificity. Curr Med Chem 19: 5232-5237.
30. Zavyalova E, Golovin A, Pavlova G, Kopylov A (2013) Module-activity relationship of G-quadruplex based DNA aptamers for human thrombin. Curr Med Chem 20: 4836-4843.
31. Serruys PW, Vranckx P, Allikmets K (2006) Clinical development of bivalirudin (Angiox): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes. Int J Clin Pract 60: 344-350.
32. Zavyalova EG, Protopopova AD, Yaminsky IV, Kopylov AM (2012) Kinetic characterization of inhibition of human thrombin with DNA aptamers by turbidimetric assay. Anal Biochem 421: 234-239.
33. Kusada A, Isogai N, Cooley BC (2007). Electric injury model of murine arterial thrombosis. Thromb Res 121: 103-106.
34. DeAnda A, Coutre SE, Moon MR, Vial CM, Griffin LC, et al. (1994) Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorae Surg 58: 344-350.
35. Griffin LC, Toole JJ, Leung LLK (1993) The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene 137: 25-31.
36. Diener JL, Wagner-Whyte J, Fontana D (2007) Aptamers that bind thrombin and with high affinity. Patent WO 2007/025049 A2, March 1, 2007.
37. Hugues J (1953) Contribution a l'etude des facteurs vasculaires et sanguins dans l'hemostase spontanee. Arch Int Physiol 61: 565-711.
38. Dejana E, Villa S, De Gaetano G (1982) Bleeding time in rats: a comparison of different experimental conditions. J Thromb Haemost 48: 108-111.
39. Kurz KD, Main BW, Sandusky GE (1990) Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60: 269-280.
40. Wang X, Xu L (2005) An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res 115: 95-100.
41. Cooley BC, Chen CY, Schmeling G (2007) Increased venous versus arterial thrombosis in the Factor V Leiden mouse. Thromb Res 119: 747-751.
42. Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, et al. (2008) Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 6: 1558-1564.
43. Heran C, Morgan S, Kasiewski C, Bostwick J, Bentley R, et al. (2000) Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur J Pharmacol 389: 201-207.
44. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP (1998) Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97: 1002-1008.
45. Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, et al. (1991) The characterization of thrombus development in an improved model of arteriovenous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin and iloprost. J Thromb Haemost 65: 268-274.
46. Mizurini DM, Francischetti IM, Monteiro RQ (2013) Aegyptin inhibits collagen-induced coagulation activation in vitro and thromboembolism in vivo. Biochem Biophys Res Commun 436: 235-239.
47. Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, et al. (1998) Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br J Pharmacol 123: 92-96.
48. Xiong J, Fang W, Fang W, Bai L, Huo J, et al. (2009) Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp). J Pharm Pharmacol 61: 89-94.
49. Berry CN, Girard D, Lochot S, Lecoffre C (1994) Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 113: 1209-1214.
50. Freund M, Cazenave J-P, Courtney M, Degryse E, Roitsch C, et al. (1990) Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. J Thromb Haemost 63: 187-192.
51. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, et al. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 3: 514-521.
52. Kaptanoglu L, Kucuk HF, Colak E, Kurt N, Bingul SM, et al. (2008) The effect of taurolidine on experimental thrombus formation. Eur J Pharmacol 578: 238-241.
53. Brundish D, Bull A, Donovan V, Fullerton JD, Garman SM, et al. (1999) Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency. J Med Chem 42: 4584-4603.
54. Rosenblum WI, El-Sabban F (1977) Platelet aggregation in the cerebral microcirculation: effect of aspirin and other agents. Circ Res 40: 320-328.
55. Valenzeno DP (1987) Photomodification of biological membranes with emphasis on singlet oxygen mechanisms. Photochem Photobiol 46: 147-160.
56. Berry CN, Lunven C, Lechaire I, Girardot C, O'Connor SE (1998) Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. Br J Pharmacol 125: 29-34.
57. Guarini S (1996) A highly reproducible model of arterial thrombosis in rats. J Pharmacol Toxicol Methods 35: 101-105.
58. Hladovec J (1971) Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemorrh 29: 407-410.
59. Diaz JA, Wrobleski SK, Hawley AE, Lucchesi BR, Wakefield TW, et al. (2011) Electrolytic inferior vena cava model (EIM) of venous thrombosis. J Vis Exp 53: e2737.